There is limited information about mortality rates among patients with psoriasis and psoriatic arthritis (PsA) in North America and their change over the past 2 decades. To compare all-cause and cause-specific mortality rates in patients with psoriasis to the general population in Ontario, Canada, from 1996 to 2016. We conducted a population-based, retrospective cohort study of adult residents using administrative health data. All-cause and cause-specific standardized mortality rates, standardized mortality ratios, and excess mortality rates were calculated. 176,858 (2,524 deaths) patients with psoriasis and 15,430 (221 deaths) patients with PsA were identified in 2016. Patients with psoriasis and PsA had standardized excess mortality rates of 1.44 and 2.43 per 1000 population, respectively. Standardized mortality rates decreased by approximately 30% over the study period in both disease groups but remained significantly elevated compared to the general population. The leading causes of death in psoriasis and PsA patients were cancer, circulatory disease, and respiratory conditions. We were unable to classify patients according to disease severity. Despite improvements in psoriasis treatment, the relative excess mortality, which may be related to risk factors for psoriatic disease, remained unchanged, with an average of approximately 1 to 2 extra deaths per 1,000 patients in 2016.

中文翻译：

---

加拿大安大略省银屑病和银屑病关节炎患者的死亡率和特定原因死亡率趋势

有关北美银屑病和银屑病关节炎 (PsA) 患者死亡率及其过去 20 年变化的信息有限。为了比较 1996 年至 2016 年加拿大安大略省银屑病患者与普通人群的全因死亡率和特定原因死亡率。我们利用管理健康数据对成年居民进行了一项基于人群的回顾性队列研究。计算全因和特定原因标准化死亡率、标准化死亡率和超额死亡率。 2016 年，共确定了 176,858 名银屑病患者（2,524 例死亡）和 15,430 名银屑病关节炎患者（221 例死亡）。银屑病和银屑病关节炎患者的标准化超额死亡率分别为每 1000 人 1.44 人和 2.43 人。在研究期间，两个疾病组的标准化死亡率均下降了约 30%，但与一般人群相比仍显着升高。银屑病和银屑病关节炎患者死亡的主要原因是癌症、循环系统疾病和呼吸系统疾病。我们无法根据疾病严重程度对患者进行分类。尽管银屑病治疗有所改善，但相对超额死亡率（可能与银屑病危险因素有关）保持不变，2016 年每 1,000 名患者平均约有 1 至 2 名额外死亡。